Does suppletion of vitamine D3 (cholecalciferol) have an effect on the systolic blood pressure in hypertensive, vitamin D insufficient patients? 1. H0 hypothesis: there is no effect on the systolic blood pressure; 2. H1 hypothesis: the systolic…
ID
Bron
Verkorte titel
Aandoening
systolic hypertension, vitamin D insufficiency.
systole hypertensie, vitamine D insufficientie.
Ondersteuning
Drs. W.J. Liefers, hospital pharmacist in training.
http://www.bronovo.nl/Bronovo/en-GB/bronovo/about_bronovo/research_fund/
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Systolic blood pressure.
Achtergrond van het onderzoek
Vitamin D insufficiency is common because of lack of sunshine exposure and too little availability of vitamin-D-rich foodsources. Low vitamin D concentrations are associated with an increased risk of
hypertension, diabetes and cardiovascular diseases, such as myocardial infarction. Suppletion of vitamin D
reduces the all-cause mortality in especially the elderly. Research in relation to low vitamin D concentrations and hypertension shows that:
1. The prevalence of hypertension increases when distance to the equator increases;
2. In winter measured blood pressures are higher;
3. Relative risk to hypertension increases strongly with 25-hydroxycholecalciferol concentrations below 37,5
nmol/l;
4. In the vitamin D insufficient, hypertensive elderly suppletion of the combination of calcium and vitamine
D shows larger decreases in systolic blood pressure and PTH than suppletion of calcium alone;
5. The plasma renin activity (PRA) increases with decreasing vitamin D concentrations.
In this double blind, randomised, placebo-controlled intervention study we want to evaluate the effect of cholecalciferol supplection on the systolic blood pressure in hypertensive patients
with a 25-hydroxycholecalciferol insufficiency. Secondly, the effects on PRC, aldosteron, 25-
hydroxycholecalciferol, alkaline phosphatase, PTH and the effect on the need of adjusting the
antihypertensive therapy are evaluated.
Only policlinical patients from Hospital Bronovo in The Hague, the Netherlands, can be included.
Doel van het onderzoek
Does suppletion of vitamine D3 (cholecalciferol) have an effect on the systolic blood pressure in hypertensive, vitamin D insufficient patients?
1. H0 hypothesis: there is no effect on the systolic blood pressure;
2. H1 hypothesis: the systolic blood pressure decreases with at least 5 mm Hg.
Onderzoeksopzet
1. T = 0, 6, 12 months:
A. Blood pressure;
B. Albumin;
C. For albumin corrected serum calcium;
D. Phosphate;
E. Plasma renin concentration;
F. Aldosteron;
G. 25-OH-Vitamin D;
H. 1,25-(OH)2-Vitamin D;
I. Parathyroid hormone (PTH);
J. Uric acid;
K. Alkaline phosphatase;
L. Fasting insulin;
M. Fasting glucose;
N. HbA1c;
O. CRP;
P. HsCRP;
Q. Creatinine/eGFR (MDRD);
R. Hemocytometry;
S. Triglycerides;
T. Cholesterol;
U. LDL-cholesterol;
V. FGF23 Calcium creatinine ratio in urine;
W. FGF23;
X. Calcium creatinine ratio in urine;
Y. Sodium creatinine ratio in urine;
Z. Abumin creatinine ratio in urine;
AA. Urine phosphate.
2. T = 0, 12 months:
A. 24-hr blood pressure (optional at T = 6 months).
Onderzoeksproduct en/of interventie
1. Group 1: 2 oral tablets of cholecalciferol 1000 IE (= 50 microg) each day for 12 months;
2. Group 2: 2 placebo oral tablets each day for 12 months.
Placebo tablets are manufactured by the Central Hospital Pharmacy, The Hague.
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. The patient has signed an informed consent;
2. The patient is an adult male or female (age 18 yr or above);
3. The patient is diagnosed with a systolic hypertension (> 140 mmHg);
4. The patient is vitamin D insufficient, defined as having a 25-hydroxycholecalciferol concentration between 20-50 nmol/l.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Using prescribed cholecalciferol supplement (equal to or more than 400 IE = 10 microg/day) after t = -2 months;
2. MDRD below normal for age/gender;
3. for albumin corrected serum calcium equal to or above 2,60 mmol/L;
4. Existing malignancy which is being treated;
5. Disease of Besnier-Boeck (sarcoidosis);
6. Pregnancy.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL1676 |
NTR-old | NTR1777 |
CCMO | NL26675.098.09 |
ISRCTN | ISRCTN wordt niet meer aangevraagd |
OMON | NL-OMON39286 |